<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04953117</url>
  </required_header>
  <id_info>
    <org_study_id>LP-SDCB-2020</org_study_id>
    <nct_id>NCT04953117</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Lepu® Drug Coated Balloon in Treatment of Coronary Small-vessel Disease</brief_title>
  <official_title>Assess the Safety and Efficacy of Lepu® Drug Coated Balloon Versus RESTORE® Paclitaxel Eluting Balloon for the Treatment of Coronary Small-vessel Disease: a Prospective, Multicenter, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lepu Medical Technology (Beijing) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lepu Medical Technology (Beijing) Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to verify the safety and efficacy of Lepu® Drug Coated Balloon in&#xD;
      Treatment of Coronary Small-vessel Disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study include a small vessel cohort and a very small vessel cohort. In the small vessel&#xD;
      cohort, patients with visually estimated reference vessel diameters(RVDs)≥2.0 and ≤2.75mm&#xD;
      were randomly assigned to the Coronary Drug Coated Balloon Catheter Used in Small Vessels of&#xD;
      Lepu Medical or the Restore DEB in a 1:1 ratio. The study was powered to detect the&#xD;
      noninferiority of the DCB of Lepu Medical versus the Restore DEB for a primary endpoint of&#xD;
      in-segment late lumen loss(LLL) at 9 months.&#xD;
&#xD;
      In the very small vessel cohort, patients with RVD≥1.75 and&lt;2.0mm were treated with the DCB&#xD;
      of Lepu Medical of an appropriate size.&#xD;
&#xD;
      All subjects will been followed up for 2 years to observe the occurrence of adverse events,&#xD;
      so as to make an accurate and reliable evaluation of the safety of drug coated balloon&#xD;
      catheters for coronary small vessels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-segment late lumen loss(LLL)</measure>
    <time_frame>9 months</time_frame>
    <description>In-segment late lumen loss is defined as the change in minimal lumen diameter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The success rate of intervention treatment (%)(Device success,Lesion success ,Procedural success)</measure>
    <time_frame>2-3 days</time_frame>
    <description>The success rate of intervention treatment (%) include device success,lesion success and procedural success</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment diameter stenosis(DS%)</measure>
    <time_frame>9 months</time_frame>
    <description>In-segment diameter stenosis(DS%) defined as (1-minimal luminal diameter[MLD]/reference vessel diameter[RVD])*100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic binary restenosis (ABR)</measure>
    <time_frame>9 months</time_frame>
    <description>Angiographic binary restenosis (ABR), defined as target lesion DS ≥ 50% at follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure (TLF)</measure>
    <time_frame>30 days,6,9 months,and 1,2 years</time_frame>
    <description>Target lesion failure (TLF), including cardiac death, target vessel-myocardial infarction (MI), or ischemic-driven target lesion revascularization (ID-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented composite endpoint (PoCE)</measure>
    <time_frame>30 days,6,9 months,and 1,2 years</time_frame>
    <description>Patient-oriented composite endpoint (PoCE), including all-cause death, all MI, or any revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite or probable target lesion thrombosis</measure>
    <time_frame>30 days,6,9 months,and 1,2 years</time_frame>
    <description>Definite or probable target lesion thrombosis, including Acute stent thrombosis, Early stent thrombosis, Late stent thrombosis, Very late stent thrombosis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">286</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>small vessel cohort: DCB of Lepu Medical</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receiving the treatment with DCB of Lepu Medical(dimeter≥2.00 mm) in small vessel cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>small vessel cohort:Restore DEB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>receiving the treatment with Restore DEB in small vessel cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>very small vessel cohort: DCB of Lepu Medical</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>receiving the treatment with DCB of Lepu Medical(dimeter&lt;2.00 mm) in very small vessel cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DCB of Lepu Medical(dimeter≥2.00 mm)</intervention_name>
    <description>subjects receiving DCB of Lepu Medical(dimeter≥2.00 mm)</description>
    <arm_group_label>small vessel cohort: DCB of Lepu Medical</arm_group_label>
    <other_name>Coronary Drug Coated Balloon Catheter of Lepu Medical for coronary small vessels</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restore DEB</intervention_name>
    <description>subjects receiving Restore DEB</description>
    <arm_group_label>small vessel cohort:Restore DEB</arm_group_label>
    <other_name>RESTORE Paclitaxel releasing coronary balloon catheter</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DCB of Lepu Medical(dimeter&lt;2.00 mm)</intervention_name>
    <description>subjects receiving DCB of Lepu Medical(dimeter&lt;2.00 mm)</description>
    <arm_group_label>very small vessel cohort: DCB of Lepu Medical</arm_group_label>
    <other_name>Coronary Drug Coated Balloon Catheter of Lepu Medical for coronary very small vessels</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age must be 18-80 years, males or females.&#xD;
&#xD;
          -  Subject with stable angina, or unstable angina, or recent myocardial infarction&#xD;
             (myocardial infarction occurred more than 7 days before enrolled into the group), or&#xD;
             asymptomatic myocardial ischemia with evidence&#xD;
&#xD;
          -  Coronary angiopathy in situ with stenosis of more than 70% with visually estimated (or&#xD;
             more than 50% combined with symptoms of ischemia, TIMI ≥ 1) in a vessel with visually&#xD;
             estimated reference vessel diameter (RVD) ≥ 2.0 mm and ≤ 2.75 mm in small vessel&#xD;
             group,and ≤ 26 mm in length or RVD ≥ 1.75 mm and &lt; 2.0 mm in very small vessel group,&#xD;
             and ≤ 16 mm in length.&#xD;
&#xD;
          -  Target small vessel lesions are located on one or two different coronary arteries (RCA&#xD;
             / LAD/ LCX). The number of target small vessel lesions on each coronary artery is no&#xD;
             more than one, and each target small vessel lesion can only be treated with one test&#xD;
             instrument&#xD;
&#xD;
          -  The number of non-target lesions requiring early interventional treatment is no more&#xD;
             than two, and the distance between them and target lesions must be &gt; 10 mm; Successful&#xD;
             treatment of non target lesions is required before subjects are randomized and the&#xD;
             test equipment(DCB) cannot be used for the treatment.&#xD;
&#xD;
          -  Subject can receive any type of coronary revascularization (including balloon&#xD;
             angioplasty, stent implantation or coronary artery bypass grafting)&#xD;
&#xD;
          -  Subject can understand the study objectives and voluntarily participate in and sign&#xD;
             the informed consent; subject must agree to clinical follow-up and angiographic&#xD;
             follow-up at 9 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AMI within 1 week.&#xD;
&#xD;
          -  In stent restenosis, complete occlusion or severe calcification (unable to pre expand&#xD;
             successfully with balloon)&#xD;
&#xD;
          -  Left main artery disease or bifurcation disease with diameter &gt;2.00mm requiring&#xD;
             interventional treatment&#xD;
&#xD;
          -  Evidence of massive thrombi in the target vessels&#xD;
&#xD;
          -  Severe heart failure (NYHA IV)&#xD;
&#xD;
          -  Severe renal failure (subject with GFR &lt; 30ml / min or undergoing hemodialysis)&#xD;
&#xD;
          -  Subject with vein graft restenosis after bypass surgery or severe heart valve disease&#xD;
&#xD;
          -  Pregnant or nursing subjects&#xD;
&#xD;
          -  Life expectancy less than 12 months&#xD;
&#xD;
          -  Subject with bleeding tendency, history of active peptic ulcer, suffered stroke within&#xD;
             the past 6 months, contraindications of antiplatelet preparation and anticoagulant&#xD;
             treatment&#xD;
&#xD;
          -  Subject is currently participating in another investigational drug or device study&#xD;
             that has not yet completed its primary endpoint.&#xD;
&#xD;
          -  Subject has undergone heart transplantation&#xD;
&#xD;
          -  Known allergy to aspirin, clopidogrel, heparin, contrast media, and paclitaxel.&#xD;
&#xD;
          -  The investigator judged that the subject's compliance is poor and can not complete the&#xD;
             study as required.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yida Tang</last_name>
    <role>Study Chair</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ting Zhang</last_name>
    <phone>+86-010-80120666</phone>
    <email>ting_zhang@lepumedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Zeng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yida Tang</last_name>
    </contact>
    <contact_backup>
      <last_name>Guisong Wang</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital, Cpaital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lefeng Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Shougang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang Tang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lianglong Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>50031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gang Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>No.980 Hospital of Joint Logistics Support Force</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>50082</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leisheng Ru</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daqing Oilfield General Hospital</name>
      <address>
        <city>Daqing</city>
        <state>Heilongjiang</state>
        <zip>163411</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Chang chun</city>
        <state>Jilin</state>
        <zip>130041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inner Mongolia People's Hospital</name>
      <address>
        <city>Hohhot</city>
        <state>Neimenggu</state>
        <zip>010017</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xi Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital,School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guosheng Fu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310058</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Jiang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>June 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Coated Balloon Catheter</keyword>
  <keyword>Small Coronary Vessel Disease</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

